Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent? Academic Article uri icon

Overview

MeSH Major

  • Alendronate
  • Bone Density Conservation Agents
  • Bone Resorption
  • Femur
  • Fractures, Bone
  • Osteogenesis Imperfecta
  • Recombinant Fusion Proteins

abstract

  • The optimal drug therapy for long-term treatment of patients with moderate-to-severe OI is unknown. Based on bone compositional changes in mice, antiresorptive treatments are useful for continued treatment in OI. There is a reported sexual dimorphism in fracture incidence in adults with OI, but to date, no one has reported differences in response to pharmaceutical intervention. This study suggests that such an investigation is warranted.

publication date

  • August 3, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4488219

Digital Object Identifier (DOI)

  • 10.1007/s11999-015-4268-z

PubMed ID

  • 25903941

Additional Document Info

start page

  • 2587

end page

  • 98

volume

  • 473

number

  • 8